Tus%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520qd

## TUSQ-QD ### Overview TUSQ-QD is a combination product containing **tuberculosis (TB) medications** in a single tablet, intended for the treatment of latent tuberculosis infection (LTBI) or active TB disease. The exact components and their proportions can vary by formulation. It is crucial to consult the specific product's labeling for exact strengths. ### Primary Indications * Treatment of latent tuberculosis infection (LTBI). * Treatment of active tuberculosis (TB) disease. ### Adult Dosing Dosing is highly dependent on the specific formulation and the patient's weight and indication (LTBI vs. active TB). Common regimens that may be found in combination products include: * **Rifampin 300 mg / Isoniazid 150 mg / Pyrazinamide 500 mg / Ethambutol 275 mg:** Often dosed once daily, typically based on weight. For example, a common weight-based dose might be 2 tablets for patients weighing 40-54 kg, and 3 tablets for patients weighing 55-70 kg. * **Rifampin 150 mg / Isoniazid 100 mg:** This combination is more commonly used for LTBI. Dosing is typically once daily, weight-based (e.g., 1 tablet for < 50 kg, 2 tablets for ≥ 50 kg). **Consult local TB treatment guidelines and the specific product monograph for precise dosing based on indication and patient weight.** ### Pediatric Dosing Pediatric dosing for combination TB medications is complex and often managed with individually dosed components rather than fixed-dose combinations due to weight variations and safety concerns. If a TUSQ-QD formulation is approved and prescribed for pediatric use, dosing will be strictly weight-based and must be determined by a pediatric TB specialist or according to established pediatric TB treatment guidelines. **There is limited information on specific pediatric dosing for fixed-dose combination products like TUSQ-QD. Pediatric use should be guided by expert consensus and approved labeling.** ### Dose Adjustments * **Renal Impairment:** Pyrazinamide and ethambutol may require dose adjustments in severe renal impairment (CrCl < 30 mL/min). Specific guidance should be sought from product labeling or renal dose adjustment guidelines. * **Hepatic Impairment:** All components of TB regimens, especially isoniazid and rifampin, can cause hepatotoxicity. Dose reduction or discontinuation may be necessary, and close monitoring is essential. ### Contraindications * Hypersensitivity to any of the components. * Severe hepatic disease (especially with isoniazid and rifampin). * Acute gout (contraindication for pyrazinamide). * Optic neuritis (contraindication for ethambutol). ### Adverse Effects Common adverse effects include: * **Hepatotoxicity:** Elevated liver enzymes, jaundice. * **Gastrointestinal:** Nausea, vomiting, abdominal pain, anorexia. * **Neurological:** Peripheral neuropathy (isoniazid), dizziness, headache. * **Ocular:** Visual disturbances, decreased visual acuity, color vision changes (ethambutol). * **Dermatological:** Rash, pruritus. * **Hematological:** Thrombocytopenia, leukopenia (rifampin). * **Other:** Arthralgia, hyperuricemia (pyrazinamide). ### Key Drug Interactions * **CYP450 Interactions:** Rifampin is a potent inducer of CYP enzymes, affecting the metabolism of numerous drugs (e.g., oral contraceptives, warfarin, protease inhibitors, corticosteroids, certain antifungals). * **Isoniazid:** Can inhibit CYP2C19 and CYP3A4, and its metabolism is affected by CYP2E1 inhibitors/inducers. It can also interact with phenytoin and other drugs metabolized by CYP2C19. * **Aluminum-containing antacids:** May decrease absorption of isoniazid and rifampin. Separate administration by at least 2 hours. ### Monitoring * **Liver Function Tests (LFTs):** Baseline and periodically throughout treatment, especially in patients with risk factors for liver disease. * **Vision Testing:** Baseline and periodically for patients receiving ethambutol. * **Uric Acid Levels:** Particularly important for patients with gout or risk factors. * **Complete Blood Count (CBC):** Periodically, especially for patients at risk of hematologic side effects. * **Renal Function:** Monitor in patients with pre-existing renal disease or those on potentially nephrotoxic agents. * **Adherence:** Crucial for treatment success. ### Clinical Pearls * Fixed-dose combinations improve adherence but limit dose individualization. Ensure the fixed dose aligns with weight-based recommendations and patient needs. * Hepatotoxicity is a significant concern. Educate patients on signs and symptoms and counsel on alcohol use. * Peripheral neuropathy with isoniazid can be reduced by co-administration of pyridoxine (vitamin B6). * Ethambutol requires ophthalmologic monitoring; discontinue if visual changes occur. * Rifampin can cause orange-red discoloration of urine, feces, sweat, and tears. **Disclaimer:** This information is for educational purposes only and does not substitute for professional medical advice. Always verify current prescribing information, local guidelines, and patient-specific factors before making any treatment decisions.